News
In adults with obesity and prediabetes, weight loss achieved with tirzepatide was sustained at more than 3 years, according ...
New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and ...
Some new medications in development are also trying to solve for a persistent side effect of existing drugs: Patients who ...
Eli Lilly said on Saturday its experimental pill orforglipron helped diabetics lose weight and lower their blood sugar, and ...
The race to develop muscle-preserving treatments alongside popular obesity drugs like Eli Lillys (NYSE:LLY) Zepbound and Novo ...
Analysts have projected that obesity drugs sales could reach $150 billion a year by the early 2030s. The unmet need to ...
GLP-1 drugs such as Wegovy and Zepbound are growing increasingly prominent. But some food ingredients can also cause the body ...
A radical shifting of trade flows has given Ireland the second-biggest trade imbalance with the U.S. after China, mostly due to demand for weight-loss drugs.
Providing a diverse range of perspectives from bullish to bearish, 7 analysts have published ratings on Eli Lilly LLY -1.05% ...
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...
AstraZeneca signed a potential $5 billion research deal with Chinese drugmaker CSPC. Eli Lilly is buying Verve Therapeutics for $1 billion upfront plus a CVR potentially worth another $300 million.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results